-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Mersana Therapeutics (NASDAQ:MRSN) Trading Up 3.7%
Mersana Therapeutics (NASDAQ:MRSN) Trading Up 3.7%
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating)'s stock price was up 3.7% during mid-day trading on Friday . The company traded as high as $6.66 and last traded at $6.66. Approximately 2,607 shares traded hands during trading, a decline of 100% from the average daily volume of 1,150,149 shares. The stock had previously closed at $6.42.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on MRSN shares. Wedbush reiterated an "outperform" rating on shares of Mersana Therapeutics in a research report on Tuesday, August 9th. SVB Leerink increased their target price on Mersana Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th. Finally, Robert W. Baird increased their target price on Mersana Therapeutics from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th.
Get Mersana Therapeutics alerts:Mersana Therapeutics Stock Up 5.3 %
The stock has a market capitalization of $656.87 million, a price-to-earnings ratio of -2.76 and a beta of 1.75. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.18. The business's 50-day moving average is $6.88 and its two-hundred day moving average is $5.05.
Mersana Therapeutics (NASDAQ:MRSN – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.05). Mersana Therapeutics had a negative net margin of 3,057.88% and a negative return on equity of 140.57%. The business had revenue of $4.28 million for the quarter, compared to analysts' expectations of $3.18 million. Equities analysts anticipate that Mersana Therapeutics, Inc. will post -1.69 EPS for the current year.Institutional Trading of Mersana Therapeutics
Large investors have recently bought and sold shares of the business. Victory Capital Management Inc. purchased a new position in shares of Mersana Therapeutics during the 1st quarter worth $36,000. Quantbot Technologies LP purchased a new position in Mersana Therapeutics during the 1st quarter valued at about $37,000. Washington University purchased a new position in Mersana Therapeutics during the 2nd quarter valued at about $43,000. Virtu Financial LLC purchased a new position in Mersana Therapeutics during the 1st quarter valued at about $53,000. Finally, Point72 Hong Kong Ltd purchased a new position in Mersana Therapeutics during the 4th quarter valued at about $57,000. Hedge funds and other institutional investors own 95.12% of the company's stock.
About Mersana Therapeutics
(Get Rating)
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
Further Reading
- Get a free copy of the StockNews.com research report on Mersana Therapeutics (MRSN)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Declining Profits Challenge the CarMax Value Proposition
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Rating)'s stock price was up 3.7% during mid-day trading on Friday . The company traded as high as $6.66 and last traded at $6.66. Approximately 2,607 shares traded hands during trading, a decline of 100% from the average daily volume of 1,150,149 shares. The stock had previously closed at $6.42.
默薩納治療公司(納斯達克代碼：MRSN-GET Rating)週五午盤股價上漲3.7%，最高報6.66美元。全天約有2,607股股票易手，較平均日成交量1,150,149股下跌100%。此前該股收盤價為6.42美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
A number of research analysts have recently issued reports on MRSN shares. Wedbush reiterated an "outperform" rating on shares of Mersana Therapeutics in a research report on Tuesday, August 9th. SVB Leerink increased their target price on Mersana Therapeutics from $13.00 to $14.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th. Finally, Robert W. Baird increased their target price on Mersana Therapeutics from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday, August 9th.
一些研究分析師最近發佈了關於MRSN股票的報告。韋德布什在8月9日星期二的一份研究報告中重申了對Mersana治療公司股票的“跑贏大盤”評級。SVB Leerink在8月9日週二的一份研究報告中將Mersana Treateutics的目標價從13.00美元上調至14.00美元，並給予該公司“跑贏大盤”的評級。最後，Robert W.Baird在8月9日星期二的一份研究報告中將Mersana Treeutics的目標價從18.00美元上調至20.00美元，並給予該公司“跑贏大盤”的評級。
Mersana Therapeutics Stock Up 5.3 %
Mersana治療公司股價上漲5.3%
The stock has a market capitalization of $656.87 million, a price-to-earnings ratio of -2.76 and a beta of 1.75. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.18. The business's 50-day moving average is $6.88 and its two-hundred day moving average is $5.05.
該股市值為6.5687億美元，市盈率為-2.76倍，貝塔係數為1.75。該公司的速動比率為3.32，流動比率為3.32，債務權益比為0.18。該業務的50日移動均線切入位在6.88美元，200日移動均線切入位在5.05美元。
Institutional Trading of Mersana Therapeutics
Mersana治療公司的機構交易
Large investors have recently bought and sold shares of the business. Victory Capital Management Inc. purchased a new position in shares of Mersana Therapeutics during the 1st quarter worth $36,000. Quantbot Technologies LP purchased a new position in Mersana Therapeutics during the 1st quarter valued at about $37,000. Washington University purchased a new position in Mersana Therapeutics during the 2nd quarter valued at about $43,000. Virtu Financial LLC purchased a new position in Mersana Therapeutics during the 1st quarter valued at about $53,000. Finally, Point72 Hong Kong Ltd purchased a new position in Mersana Therapeutics during the 4th quarter valued at about $57,000. Hedge funds and other institutional investors own 95.12% of the company's stock.
大型投資者最近買賣了該公司的股票。勝利資本管理公司在第一季度購買了價值3.6萬美元的Mersana治療公司的新股票頭寸。Quantbot Technologies LP在第一季度購買了Mersana治療公司的一個新頭寸，價值約3.7萬美元。華盛頓大學在第二季度購買了Mersana治療公司的一個新頭寸，價值約43,000美元。Virtu Financial LLC在第一季度購買了Mersana Treeutics的一個新頭寸，價值約53,000美元。最後，Point72 Hong Kong Ltd在第四季度購買了Mersana Treeutics的新頭寸，價值約57,000美元。對衝基金和其他機構投資者持有該公司95.12%的股票。
About Mersana Therapeutics
關於Mersana Treeutics
(Get Rating)
(獲取評級)
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
Mersana治療公司是一家臨牀階段生物製藥公司，為未得到滿足需求的癌症患者開發抗體藥物結合物(ADC)。它開發了XMT-1592，一種針對NaPi2b表達腫瘤細胞的Dolasynten ADC，正在進行治療卵巢癌和NSCLC腺癌的I期臨牀試驗。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Mersana Therapeutics (MRSN)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Declining Profits Challenge the CarMax Value Proposition
- 免費獲取StockNews.com關於Mersana治療公司(MRSN)的研究報告
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat：回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- 雷神工業走出谷底
- 利潤下降對CarMax價值主張的挑戰
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Mersana治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Mersana Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧